Ciphero | $2,500,000 | (Dec 23, 2025)
beycome | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)
Athernal Bio
United Kingdom
- Cambridge
- 02/10/2025
- Unknown
- $4,718,630
Developing targeted immunotherapies to treat high-risk clonal haematopoiesis (CH)—the precursor to blood cancers—so we can stop cancer before it starts.
- Industry Biotechnology Research
- Website https://www.athernalbio.com/
- LinkedIn https://www.linkedin.com/company/athernal-bio/
Related People
Colin FreundFounder
United States -
New York City Metropolitan Area
C-level executive with experience in both private and public biotechnology companies, with 18 years' experience leading multinational teams that drive revenue generation and corporate value creation: company leadership (including venture fundraising); strategic planning, business/corporate development and M&A ($500M+ in multiple licensing/M&A transactions); corporate restructuring; alliance management; commercial development and product launch preparation; supply chain optimization; organizational development; investor relations/fundraising; and business interface on regulatory strategy in the USA, Europe and Asia.
StretchSense | $2,300,000 | (Dec 23, 2025)
ZeroPhase | $6,800,000 | (Dec 23, 2025)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ethereal Exploration Guild | $21,000,000 | (Dec 23, 2025)
LatentForce | $1,700,000 | (Dec 23, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Amphix Bio | $12,500,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)